Drug search by name

Rabeprazole Delayed-Release Tablets and Liver disease

Result of checking the interaction of drug Rabeprazole Delayed-Release Tablets and disease Liver disease for safety when used together.

Check result:

Rabeprazole Delayed-Release Tablets <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Rabeprazole is primarily metabolized by the liver. Although the drug is generally well-tolerated, therapy with rabeprazole should be administered cautiously in patients with severe liver disease because of the lack of clinical data concerning its use in such patients. Dosage adjustments are not necessary in patients with mild to moderate hepatic impairment.

References:

"Product Information. Aciphex (rabeprazole)" Janssen Pharmaceuticals, Titusville, NJ.
Prakash A, Faulds D "Rabeprazole." Drugs 55 (1998): 261-7;disc. 268
Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ "Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis." Clin Ther 21 (1999): 691-701

Rabeprazole Delayed-Release Tablets

Generic Name: rabeprazole

Brand Name: Aciphex, AcipHex Sprinkle

Synonyms: Rabeprazole, RABEprazole

What is Rabeprazole Delayed-Release Tablets?